All In Biotech

Drug Trial Radar · NCT04076371

The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Sep 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,640 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,640

Actual

Start

Jan 2012

Primary completion

Dec 2018

Study completion Dec 2018

Sponsor

Lead sponsor
Beijing HuiLongGuan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients

Conditions

  • Schizophrenia

Interventions

  • olanzapine-sertraline combinationDrug

    the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)

  • only olanzapineDrug

    the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)

  • risperidone-sertraline combinationDrug

    the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)

  • only risperidoneDrug

    the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)

  • paliperidone-sertraline combinationDrug

    the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)

  • only paliperidoneDrug

    the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)

  • ziprasidone-sertraline combinationDrug

    the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)

  • only ziprasidoneDrug

    the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. changes in psychopathology symptoms on PANSS during antipsychiatric treatmentTime frame: baseline, week 4, week 8, week 12, and week 24
  2. changes in depressive symptoms on HAMD during antipsychiatric treatmentTime frame: baseline, week 4, week 8, week 12, and week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.